Society for Maternal-Fetal Medicine (SMFM)

The audit

Who controls it

SMFM specialty statements are developed through clinician expert committees and its publications process. Its membership includes an industry-professional category, but the reviewed material did not place those members or sponsors in a particular statement's authoring or approval chain.

Money

SMFM's return for the year ending December 2025 reports $10,346,279 in revenue and $2,126,055 in contributions, or 20.5%; donor sectors are not identified. It markets sponsorships and exhibits, but the amount and industry share were not verified, and its public annual-report index reviewed here stopped at 2022.

Conflict rules

SMFM's public policy covers financial and nonfinancial interests, family relationships, and disclosures before service or publication, with updates during service. It describes a three-year look-back, a one-year look-forward, and a $1,000 compensation threshold for specified financial relationships.

Method

SMFM adopted GRADE in 2013 and updated its process in 2021; its special-statement method describes evidence review and recommendation grading. The process is document-specific, and SMFM notes that its publications do not receive additional editorial or peer review by the journal Pregnancy.

Dates on its pages

SMFM's reviewed materials did not establish a portfolio-wide update schedule or a typical age for its guidance; publication dates and revision histories vary by document.

Political exposure

In 2026, SMFM issued an abortion-restrictions statement that replaced its 2022 statement, and the Society of Family Planning endorsed it in July 2026. The reviewed record showed no political officials directing that revision, and the historical scan was not exhaustive.

Money exposure

As of the October 14, 2026 audit, SMFM openly marketed industry sponsorships and exhibits and offered a membership class for industry professionals, but the revenue share was unverified. The reviewed sources did not show that a sponsor changed a particular recommendation.

Track record

In the acetaminophen backtest, SMFM responded on September 22, 2025, and a June 1, 2026 statement reaffirmed first-line use while noting limits in the research. The statement gave no effect estimates, no usable archive capture was retrieved, and it preceded later 2026 studies reviewed in that test.

Where this comes from

• SMFM 2025 tax return record
• SMFM disclosure of interest policy
• SMFM GRADE statement method
• SMFM industry partners and sponsorship
• SMFM 2026 abortion-restrictions statement